388 related articles for article (PubMed ID: 21346614)
41. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.
de Oliveira MVS; de Barros PMF; de Mathis MA; Boavista R; Chacon P; Echevarria MAN; Ferrão YA; Vattimo EFQ; Lopes AC; Torres AR; Diniz JB; Fontenelle LF; Rosário MCD; Shavitt RG; Miguel EC; da Silva RMF; Costa DLDC
Braz J Psychiatry; 2023 May; 45(2):146-161. PubMed ID: 36749887
[TBL] [Abstract][Full Text] [Related]
42. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.
Tundo A; Salvati L; Cieri L; Balestrini V; Di Spigno D; Orazi F; Iommi M; Necci R
Int J Psychiatry Clin Pract; 2022 Nov; 26(4):395-400. PubMed ID: 35323098
[TBL] [Abstract][Full Text] [Related]
43. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.
Connor KM; Payne VM; Gadde KM; Zhang W; Davidson JR
J Clin Psychiatry; 2005 Jan; 66(1):49-51. PubMed ID: 15669888
[TBL] [Abstract][Full Text] [Related]
44. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
45. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder.
Koran LM; Sallee FR; Pallanti S
Am J Psychiatry; 1997 Mar; 154(3):396-401. PubMed ID: 9054789
[TBL] [Abstract][Full Text] [Related]
46. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis.
Maiti R; Mishra A; Srinivasan A; Mishra BR
Acta Psychiatr Scand; 2023 Jul; 148(1):19-31. PubMed ID: 37177823
[TBL] [Abstract][Full Text] [Related]
47. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
[TBL] [Abstract][Full Text] [Related]
48. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
Ammar G; Naja WJ; Pelissolo A
Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
[TBL] [Abstract][Full Text] [Related]
49. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
50. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
Varigonda AL; Jakubovski E; Bloch MH
J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
[TBL] [Abstract][Full Text] [Related]
51. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
Mowla A; Boostani S; Dastgheib SA
J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
[TBL] [Abstract][Full Text] [Related]
52. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].
Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ
BMC Psychiatry; 2005 Jan; 5():5. PubMed ID: 15667657
[TBL] [Abstract][Full Text] [Related]
53. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
Francobandiera G
Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
[TBL] [Abstract][Full Text] [Related]
54. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Hollander E; Baldini Rossi N; Sood E; Pallanti S
Int J Neuropsychopharmacol; 2003 Dec; 6(4):397-401. PubMed ID: 14604454
[TBL] [Abstract][Full Text] [Related]
55. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Pallanti S; Quercioli L; Koran LM
J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
[TBL] [Abstract][Full Text] [Related]
56. A Comparative Study of Aripiprazole, Olanzapine, and L-Methylfolate Augmentation in Treatment Resistant Obsessive-Compulsive Disorder.
Dar SA; Wani RA; Haq I
Psychiatr Q; 2021 Dec; 92(4):1413-1424. PubMed ID: 33830427
[TBL] [Abstract][Full Text] [Related]
57. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
Zohar J; Judge R
Br J Psychiatry; 1996 Oct; 169(4):468-74. PubMed ID: 8894198
[TBL] [Abstract][Full Text] [Related]
58. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder.
Koran LM; Aboujaoude E; Ward H; Shapira NA; Sallee FR; Gamel N; Elliott M
J Clin Psychopharmacol; 2006 Feb; 26(1):79-83. PubMed ID: 16415712
[TBL] [Abstract][Full Text] [Related]
59. Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment.
Mundo E; Bellodi L; Smeraldi E
Biol Psychiatry; 1995 Oct; 38(8):525-31. PubMed ID: 8562664
[TBL] [Abstract][Full Text] [Related]
60. [Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials].
Dold M; Aigner M; Lanzenberger R; Kasper S
Fortschr Neurol Psychiatr; 2011 Aug; 79(8):453-66. PubMed ID: 21809258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
